Healio (11/11, Rhoades) reported, “A 25 mg dose of psilocybin was associated with improvements in treatment-resistant depression over a three-week period, but with adverse events,” researchers concluded in the findings of a 233-patient, phase 2 study published online Nov. 3 in the New England Journal of Medicine. (SOURCE: APA Headlines)